Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was up 19% during mid-day trading on Wednesday . The stock traded as high as C$0.13 and last traded at C$0.13. Approximately 291,000 shares changed hands during trading, a decline of 13% from the average daily volume of 332,835 shares. The stock had previously closed at C$0.11.
Hemostemix Price Performance
The company’s 50 day simple moving average is C$0.09 and its 200 day simple moving average is C$0.07. The company has a market capitalization of C$20.91 million, a PE ratio of -12.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- The 3 Best Blue-Chip Stocks to Buy Now
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How Investors Can Find the Best Cheap Dividend Stocks
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
